In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.

doi:10.1126/sciadv.adl4013

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.

Science advances - 26 Jul 2024

Zhu Yuao, Yurgelonis Irina, Noell Stephen, Yang Qingyi, Guan Shunjie, Li Zhenghui, Hao Li, Rothan Hussin, Rai Devendra K, McMonagle Patricia, Baniecki Mary Lynn, Greasley Samantha E, Plotnikova Olga, Lee Jonathan, Nicki Jennifer A, Ferre RoseAnn, Byrnes Laura J, Liu Wei, Craig Timothy K, Steppan Claire M, Liberator Paul, Soares Holly D, Allerton Charlotte M N, Anderson Annaliesa S, Cardin Rhonda D

Abstract excerpt

To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus Mpro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six Mpro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coronavirus 3C Proteases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to COVID-19 Drug Treatment

Source

Open in PubMed Open full text

Identifiers

PMID: 39047088
DOI: 10.1126/sciadv.adl4013
PMCID: PMC11268423

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.PMID 39047088Read ↗

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity Read ↗

Rapid resistance profiling of SARS-CoV-2 protease inhibitorsSemantic proximity Read ↗

An Investigation of Nirmatrelvir (Paxlovid) Resistance in SARS-CoV-2 MproSemantic proximity Read ↗

Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main proteaseSemantic proximity Read ↗

Rapid resistance profiling of SARS-CoV-2 protease inhibitorsSemantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

Rapid resistance profiling of SARS-CoV-2 protease inhibitorsSemantic proximity Read ↗

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity Read ↗

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor <i>in vitro</i> and confer resistance to nirmatrelvirSemantic proximity Read ↗

Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.Semantic proximity Read ↗

Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.